Healthcare: IBA and Tractebel agree on partnership to support proton therapy construction projects

15 Mar 2022

Tractebel and IBA, the world leader in particle accelerator technology, join forces to support the construction of proton therapy facilities that contribute to treating cancer around the world. 

Tractebel and IBA have signed a partnership agreement to strengthen their cooperation in the field of proton therapy, an advanced form of radiation therapy designed to kill cancer cells. The agreement provides that IBA will promote Tractebel’s engineering services to its prospective customers to help them design and build proton therapy facilities.  

Tractebel has unique experience in providing engineering services, consultancy and training for complex healthcare projects. This will enable us to complement IBA’s offering of world-class proton therapy technology solutions by supporting healthcare players in the construction process of the buildings that host the technology.  

To provide customers with more information on proton therapy construction projects and on our expertise in this field, IBA and Tractebel will jointly carry out marketing activities and prepare extended services offerings.  

A successful collaboration 

The two companies have already collaborated on several projects, such as structural integrity reviews in the event of an earthquake, cost estimation tools for IBA’s Proteus facilities, stability studies related to the installation of a compact proton therapy unit into an existing one, and engineering support for the design of proton therapy facilities including BIM modelling. 

Luk Herremans (Executive Vice President Commercial Operations Proton Therapy, IBA), Bernard Dereeper (Head of Business Development & Strategy – Business Line Nuclear, Tractebel) and Denis Dumont (General Manager Business Line Nuclear, Tractebel).

“We have worked for several years with Tractebel on a variety of projects. It has enabled Tractebel to gain an extensive knowledge of the building requirements of our proton therapy systems, making them the perfect design and engineering partner. Listening to the market, there is an obvious need for a company that can guide our customers through the design and building journey and help them to make it as efficient and smooth as possible. We look forward to collaborating with Tractebel to offer an even more complete service to the market.” 

Luk Herremans, Executive Vice President Commercial Operations Proton Therapy, IBA  

“We are honored to join forces once again with IBA, a global leader in proton therapy and medical equipment. Combining our expertise in designing medical installations, our nuclear- and radiation-related competences and our multidisciplinary approach with IBA’s world-class radiation therapy technology will enable us to offer high-level and fully integrated services from facilities design and engineering to the system itself. We are proud that our engineers’ know-how will contribute to improving cancer treatment around the world.” 

Bernard Dereeper, Head of Business Development & Strategy – Business Line Nuclear, Tractebel 

More information can be found at: www.iba-worldwide.com 

Discover more about our Nuclear4Medical solutions and Our urban healthcare references

 

 

Related news

ULB-Master-s-Graduates

Executive master’s in Resilient and Carbon-Neutral Cities: Second session slated for September 2023

Following the success of theTractebel-ENGIE-Université Libre de Bruxelles' executive master’s program, a new and improved second session will begin...

Find out more
27 Mar 2023
AdobeStock_291151342

Tractebel reaches 2022 emissions target

In 2021 Tractebel announced...

Find out more
23 Mar 2023
Banner-photo-David-Levrat

Meet David Levrat, Tractebel’s Head of Carbon & Climate

Find out more
22 Mar 2023
signing_MOU_NRGPALLAS_Tractebel

Tractebel and NRG|PALLAS join forces to support nuclear new-build in the Netherlands

Tractebel and NRG|PALLAS signed a Memorandum of Understanding to cooperate to support the new-build of nuclear power plants in the Netherlands. The signing was held at the...

Find out more
17 Mar 2023